(19)
(11) EP 1 684 805 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.08.2010 Bulletin 2010/34

(45) Mention of the grant of the patent:
21.07.2010 Bulletin 2010/29

(21) Application number: 04818358.6

(22) Date of filing: 04.11.2004
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
(86) International application number:
PCT/US2004/037281
(87) International publication number:
WO 2005/044855 (19.05.2005 Gazette 2005/20)

(54)

USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR TREATMENT OF MULTIPLE MYELOMA

VERWENDUNG VON ANTAGONISTEN-ANTI-CD40-MONOKLONALEN ANTIKÖRPERN ZUR BEHANDLUNG VON MULTIPLEM MYELOM

UTILISATION D'ANTICORPS MONOCLONAUX ANTAGONISTES ANTI-CD40 POUR LE TRAITEMENT DE MYELOME MULTIPLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 04.11.2003 US 517337 P
26.11.2003 US 525579 P
26.04.2004 US 565709 P
27.04.2004 US 565710 P

(43) Date of publication of application:
02.08.2006 Bulletin 2006/31

(73) Proprietors:
  • Novartis Vaccines and Diagnostics, Inc.
    Emeryville, CA 94608 (US)
  • XOMA Technology Ltd.
    Hamilton HM11 (BM)

(72) Inventors:
  • LONG, Li, Chiron Corporation
    Emeryville, CA 94662-8097 (US)
  • LUQMAN, Mohammad, Chiron Corporation
    Emeryville, CA 94662-8097 (US)
  • YABANNAVAR, Asha, Chiron Corporation
    Emeryville, CA 94662-8097 (US)
  • ZAROR, Isabel, Chiron Corporation
    Emeryville, CA 94662-8097 (US)

(74) Representative: Marshall, Cameron John et al
Carpmaels & Ransford One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A-01/83755
WO-A-02/28904
 WO-A-02/28480
WO-A-02/088186
   
  • TAI YU-TZU ET AL: "Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications" CANCER RESEARCH, vol. 64, no. 8, 15 April 2004 (2004-04-15), pages 2846-2852, XP002327506 ISSN: 0008-5472
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), WENG WEN-KAI ET AL: "Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma" XP002327507 Database accession no. PREV200200241215 & BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 466a, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001 ISSN: 0006-4971
  • LITTLE M. ET AL.: "Of mice and men: hybridoma and recombinant antibodies" REVIEW IMMUNOLOGY TODAY, vol. 21, pages 364-370,
  • BALINT ROBERT, LARRICK JAMES: "Antibody engineering by parsimonious mutagenesis" GENE, vol. 137, pages 109-118,
  • ELLMARK ET AL.: "Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library" IMMUNOLOGY, vol. 106, 4 August 2008 (2008-08-04), pages 456-463,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).